Amyris Inc (NASDAQ:AMRS) gapped down before the market opened on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $7.38, but opened at $5.90. Amyris shares last traded at $4.14, with a volume of 6619545 shares changing hands.

The biotechnology company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.96). The company had revenue of $14.90 million for the quarter, compared to the consensus estimate of $46.72 million. The company’s revenue was down 38.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.81) EPS.

Several brokerages recently commented on AMRS. BidaskClub upgraded shares of Amyris from a “hold” rating to a “buy” rating in a report on Wednesday, August 15th. HC Wainwright set a $15.00 price target on shares of Amyris and gave the company a “buy” rating in a report on Thursday, October 4th. Zacks Investment Research downgraded shares of Amyris from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. ValuEngine raised shares of Amyris from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 2nd. Finally, B. Riley set a $10.00 price objective on shares of Amyris and gave the company a “buy” rating in a research report on Monday, September 17th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $7.63.

In other Amyris news, Director Frank Kung sold 3,924,884 shares of the business’s stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $6.22, for a total value of $24,412,778.48. Following the completion of the sale, the director now directly owns 4,266 shares of the company’s stock, valued at approximately $26,534.52. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Kathleen Valiasek acquired 14,000 shares of the stock in a transaction on Wednesday, August 22nd. The stock was bought at an average cost of $7.20 per share, with a total value of $100,800.00. Following the completion of the transaction, the chief financial officer now owns 228,630 shares in the company, valued at $1,646,136. The disclosure for this purchase can be found here. 21.80% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Fox Run Management L.L.C. purchased a new stake in Amyris in the 3rd quarter valued at about $121,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Amyris in the 3rd quarter worth approximately $127,000. Rhumbline Advisers purchased a new stake in shares of Amyris in the 2nd quarter worth approximately $147,000. Bank of Montreal Can lifted its position in shares of Amyris by 14,604.1% in the 3rd quarter. Bank of Montreal Can now owns 25,291 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 25,119 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in shares of Amyris in the 2nd quarter worth approximately $167,000. 24.06% of the stock is owned by institutional investors.

The stock has a market capitalization of $408.28 million, a price-to-earnings ratio of -1.27 and a beta of 0.27.

WARNING: This article was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.thecerbatgem.com/2018/11/16/amyris-amrs-shares-gap-down-following-weak-earnings.html.

Amyris Company Profile (NASDAQ:AMRS)

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Featured Story: What is the NASDAQ Stock Market?

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.